Enliven Therapeutics (NASDAQ:ELVN) Posts Earnings Results, Misses Expectations By $0.10 EPS

Enliven Therapeutics (NASDAQ:ELVN) posted its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Enliven Therapeutics Trading Up 1.5%

Enliven Therapeutics stock traded up $0.87 during trading on Thursday, hitting $60.57. The company had a trading volume of 219,859 shares, compared to its average volume of 1,279,577. The company’s 50 day simple moving average is $47.81 and its 200-day simple moving average is $39.29. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32. The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -36.26 and a beta of 0.27.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares of the company’s stock, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. The trade was a 11.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,036 shares of company stock valued at $1,430,676 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Enliven Therapeutics during the fourth quarter worth approximately $83,000. Quantbot Technologies LP lifted its position in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at $191,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Guggenheim dropped their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday. The Goldman Sachs Group boosted their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday. Mizuho upped their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Finally, HC Wainwright increased their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.67.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.